EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study

Idris Bahce iD, Chris Dickhoff, Famke L Schneiders, Joris Veltman, David J Heineman, Sayed M S Hashemi, Anne Vrijmoet, Ilias Houda, Ezgi B Ulas iD, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis und 7 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009799 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Idris Bahce und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, Netherlands i.bahce@amsterdamumc.nl. Hauptthemen laut MEDLINE: Ipilimumab, Lung Neoplasms, Nivolumab, Neoadjuvant Therapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC.

Methods

This single-arm, phase-II trial enrolled operable T3-4N0–2 patients with NSCLC without oncogenic drivers. Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT, IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later. Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy. Resections were 6 weeks post-radiotherapy.

Results

In a total of 30 patients in the intention-to-treat (ITT) population, grades 3–4 treatment-related adverse events (TRAEs) occurred in 70%, one TRAE grade 5 late-onset pneumonitis on day 96 post-surgery (1/30, 3.3%) occurred, and one non-TRAE COVID-19 death (1/30, 3.3%). pCR and MPR were achieved in 50% (15/30) and 63% (19/30) of the ITT; and in 58% (15/26) and 73% (19/26) of the 26 patients who underwent surgery, respectively. Postoperative melanoma was seen in one non-pCR patient. The R0 rate was 100% (26/26), and no patient failed surgery due to TRAEs. In peripheral blood, proliferative CD8 + T cells were increased, while proliferative regulatory T cells (Tregs) were not. On-treatment, pCR-positives had higher CD8 + CD39 + T cells and lower HLA-DR + Tregs.

Conclusions

Neoadjuvant IPI-NIVO-CRT in T3-4N0–2 NSCLC showed acceptable safety with pCR and MPR in 58% and 73% of operated patients, respectively. No patient failed surgery due to TRAEs. Trial registration number NCT04245514 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabLung NeoplasmsNivolumabNeoadjuvant TherapyHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyAdultCarcinoma, Non-Small-Cell Lung

Stichwörter der Autor:innen

ChemotherapyIpilimumabNivolumabRadiotherapy

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, Netherlands i.bahce@amsterdamumc.nl.
  • Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Noord-Holland, Netherlands.
  • Department of Cardiothoracic Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Department of Radiation Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Department of Pulmonary Medicine, location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

ORCID-Profile: Idris Bahce, Ezgi B Ulas, Febe van Maldegem, Marieke F Fransen, Suresh Senan

Förderung

  • Bristol-Myers Squibb
  • Dutch Cancer Society

Zitieren

APA

Bahce, I., Dickhoff, C., Schneiders, F. L., Veltman, J., Heineman, D. J., Hashemi, S. M. S., Vrijmoet, A., Houda, I., Ulas, E. B., Bakker, J., van de Ven, P., Bouwhuis, N., Meijboom, L. J., Oprea-Lager, D. E., van Maldegem, F., Fransen, M. F., de Gruijl, T. D., Radonic, T., & Senan, S. (2024). Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009799

Vancouver

Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, et al. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009799

BibTeX
@article{Bahce2024,
  author = {Bahce, Idris and Dickhoff, Chris and Schneiders, Famke L and Veltman, Joris and Heineman, David J and Hashemi, Sayed M S and Vrijmoet, Anne and Houda, Ilias and Ulas, Ezgi B and Bakker, Joyce and van de Ven, Peter and Bouwhuis, Natalja and Meijboom, Lilian J and Oprea-Lager, Daniela E and van Maldegem, Febe and Fransen, Marieke F and de Gruijl, Tanja D and Radonic, Teodora and Senan, Suresh},
  title = {Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009799}
}
Kostenlos starten →